Pirtobrutinib

Pirtobrutinib
Clinical data
Trade names	Jaypirca
Other names	LOXO-305
AHFS/Drugs.com	Monograph
MedlinePlus	a623012
License data	US DailyMed: Pirtobrutinib;
Routes of; administration	By mouth
Drug class	Protein kinase inhibitor
ATC code	L01EL05 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide;
CAS Number	2101700-15-4;
PubChem CID	129269915;
DrugBank	DB17472;
ChemSpider	114875989;
UNII	JNA39I7ZVB;
KEGG	D12050;
ChEBI	CHEBI:229212;
ChEMBL	ChEMBL4650485;
PDB ligand	Y7W (PDBe, RCSB PDB);
Chemical and physical data
Formula	C22H21F4N5O3
Molar mass	479.436 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C=C(F)C=C1)C(=O)NCC1=CC=C(C=C1)C1=NN([C@@H](C)C(F)(F)F)C(N)=C1C(N)=O;
	InChI InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1; Key:FWZAWAUZXYCBKZ-NSHDSACASA-N;

Pirtobrutinib, sold under the brand name Jaypirca, is an anticancer medication that is used to treat mantle cell lymphoma. It inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton's tyrosine kinase (BTK). It is taken by mouth.

The most common adverse reactions include fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising. The most common adverse reactions when used to treat chronic lymphocytic leukemia or small lymphocytic leukemia include fatigue, bruising, cough, musculoskeletal pain, COVID-19, diarrhea, pneumonia, abdominal pain, dyspnea, hemorrhage, edema, nausea, pyrexia, and headache.

Pirtobrutinib was approved for medical use in the United States in January 2023, and in the European Union in November 2023.